Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Cassaday RD, Fromm JR, Fang M, Smith SD. Ho C, et al. Among authors: ujjani cs. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e33-e39.e1. doi: 10.1016/j.clml.2023.10.002. Epub 2023 Oct 18. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37926672
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M. Cooper JP, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):390-395. doi: 10.1016/j.clml.2019.03.003. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30948330
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD. Kim A, et al. Pract Radiat Oncol. 2020 Jan-Feb;10(1):44-52. doi: 10.1016/j.prro.2019.09.013. Epub 2019 Oct 1. Pract Radiat Oncol. 2020. PMID: 31585205
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: ujjani cs. Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254. Blood. 2023. PMID: 36913694 Free PMC article. Clinical Trial.
Vaccinations in CLL: implications for COVID-19.
Shadman M, Ujjani C. Shadman M, et al. Blood. 2021 Jan 14;137(2):144-146. doi: 10.1182/blood.2020009966. Blood. 2021. PMID: 33443562 Free PMC article. No abstract available.
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR. Shadman M, et al. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):515-526. doi: 10.1016/j.clml.2023.03.010. Epub 2023 Mar 24. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37076367 Free article.
53 results